Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Lemaitre Vascular (LMAT) stock in plain English

Free brief · no signupStart here
LMATPublished Nov 14, 2026
Lemaitre Vascular Inc
Healthcare · Medical Instruments & Supplies
Manufactures and distributes specialized surgical implants and disposable instruments for peripheral vascular surgery.
Assets:
Burlington facilityMain manufacturing plant and corporate headquarters located in Massachusetts
Direct sales staffOver three hundred specialized sales representatives worldwide
Vascular product linesProprietary surgical portfolio covering valvulotomes, shunts, and grafts
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

78
OPS ScoreOperating finances
Latest quote
-0.95%$74.86
$1.71B
27.7×
$269.32M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was LMAT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Lemaitre Vascular (LMAT) do?

Lemaitre Vascular Inc (LMAT) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures and distributes specialized surgical implants and disposable instruments for peripheral vascular surgery. Operates a direct sales force supplying proprietary surgical tools directly to vascular surgeons worldwide. It is worth $1.71B on the market and sold $269.32M over the last year.

Market cap
$1.71B
P/E ratio
27.7×
Annual sales
$269.32M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 14, 2026

Brands and businesses behind LMAT

  • Artegraft: Produces processed bovine carotid artery grafts sold to hospitals for vascular access and bypass procedures.
  • XenoSure: Sells bovine pericardial surgical patches used for vascular reconstruction and cardiovascular repair to surgical centers.
  • Pruitt: Supplies carotid shunts that maintain cerebral blood flow during endarterectomy operations in hospital operating rooms.
  • Omniflow: Markets biosynthetic vascular prostheses used for peripheral bypass and arteriovenous access procedures.

LMAT’s flags, in plain English

Each flag is a number from Lemaitre Vascular’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 14.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 70.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Fat Margins

Profit margin of 23.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Thinly Traded

Thinly traded, about 279 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about LMAT

How big is Lemaitre Vascular?

Lemaitre Vascular’s market cap is $1.71B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $269.32M: what customers paid the company over the last year, before any costs.

What is LMAT’s P/E ratio?

LMAT’s P/E ratio is 27.7×. Investors pay about 27.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with LMAT?

A strong U.S. dollar reduces the value of sales generated across international hospital markets. That is one risk on Lemaitre Vascular’s card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Lemaitre Vascular’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LMAT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card